What is the normal dose of Trelegy (fluticasone furoate, umeclidinium, vilanterol) for Chronic Obstructive Pulmonary Disease (COPD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Normal Dose of Trelegy for COPD

The normal dose of Trelegy for COPD is one inhalation of fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg once daily. 1

Dosing Specifications

  • Single daily inhalation: Trelegy is administered as one actuation once daily by oral inhalation 1
  • Timing consistency: The medication should be used at the same time every day 1
  • Maximum frequency: Do not use more than once every 24 hours 1

Post-Inhalation Care

  • Mouth rinsing required: After inhalation, rinse mouth with water without swallowing to reduce the risk of oropharyngeal candidiasis 1

Rescue Medication Use

  • For breakthrough symptoms: If shortness of breath occurs between doses, use an inhaled short-acting beta2-agonist (such as albuterol) for immediate relief 1
  • Not for acute relief: Trelegy is NOT indicated for relief of acute bronchospasm 1

Clinical Context for Triple Therapy

Appropriate patient selection is critical for Trelegy use:

  • Indication: Reserved for patients with persistent moderate to severe dyspnea despite dual therapy, or those at high risk of COPD exacerbations 2, 3
  • Disease severity: Recommended for patients in GOLD categories C and D with severe airflow obstruction (FEV₁ <50% predicted) and frequent exacerbations 4

Common Pitfall to Avoid

Never add additional inhaled corticosteroids (such as Pulmicort) to Trelegy, as this represents irrational polypharmacy and unnecessarily increases pneumonia risk 4. Trelegy already contains a complete triple therapy regimen with an inhaled corticosteroid component 1, 5.

References

Guideline

COPD Management with Triple and Dual Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Triple Therapy for COPD Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Prescribing Trelegy and Pulmicort Together

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is fluticasone 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder used for?
What is the most common dosing regimen of Trelegy (fluticasone furoate, umeclidinium, vilanterol) for moderate Chronic Obstructive Pulmonary Disease (COPD)?
What are the alternatives to Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) for patients who require a different treatment option?
Can a patient with Chronic Obstructive Pulmonary Disease (COPD) take Trelegy (fluticasone furoate, umeclidinium, vilanterol) and albuterol (salbutamol) for maintenance treatment?
What is the optimal management plan for a patient using Trelegy (fluticasone furoate, umeclidinium, and vilanterol) inhaler once daily for COPD (Chronic Obstructive Pulmonary Disease) or asthma?
What is the most appropriate next step in management for a patient with chronic hepatitis C, liver cirrhosis, anemia (low Hemoglobin (Hb)), thrombocytopenia (low Platelets count), coagulopathy (elevated International Normalized Ratio (INR) and prolonged Prothrombin time) presenting with a perforated peptic ulcer requiring urgent laparotomy?
What does an elevated thyroid peroxidase antibody (TPO Ab) level indicate and how is it treated?
What is the recommended protocol for switching from Effexor (venlafaxine) to Pristiq (desvenlafaxine)?
What is the approach for evaluating and treating Multiple Sclerosis (MS)?
What is antiphospholipid syndrome?
What is the justification for rotating antibiotics in a patient with a urinary tract infection (UTI) due to E. coli, currently on ertapenem (a carbapenem antibiotic), with a recent urine culture showing Pseudomonas aeruginosa resistant to ciprofloxacin (a fluoroquinolone antibiotic)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.